At a glance
ClinicalIndex Comparison RecordN/ACompleted· 415 enrolled
Drug / intervention
Low dose omega-3 fatty acid supplementation +2 moredrug
Likely dose
Low dose omega-3 fatty acid supplementation 1.5 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-blind and Placebo-controlled Study on Intervention Effect of n-3 Fatty Acids on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Populations
In Brief
A clinical study evaluating Low dose omega-3 fatty acid supplementation, High dose omega-3 fatty acid supplementation, and 1 other intervention for Hyperglycaemia (Diabetic) and Hyperlipidemias. Completed, enrolled 415 participants across 1 site.
Detailed Summary
A double-blind and placebo-controlled study is conducted in the current human study. The purpose of this study is to investigate the effects of n-3 PUFA intervention on glucose and lipid homeostasis in Chinese diabetic/obese patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperglycaemia (Diabetic), Hyperlipidemias
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartOct 2020
Primary CompletionJan 2022
Study CompletionFeb 2022
TodayJul 2026
First PostedOct 17, 2018
Enrollment StartOct 10, 2020
Primary CompletionJan 2, 2022
Study CompletionFeb 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.7 years ago
Interventions
Low dose omega-3 fatty acid supplementationdrug
Omega-3 fatty acids capsules, 1.5 g/d by mouth for 1 year
High dose omega-3 fatty acid supplementationdrug
Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year
Control drugdrug
Matching placebo capsules,3 g/d by mouth for 1 year